Iacobelli Simona

01/06/2016 Off By IMS Tor Vergata

Go to top

Subject: Physics and statistics

Go to top

email: simona.iacobelli@uniroma2.it

office: 0672594859

Go to top

ACADEMIC AND SCIENTIFIC CURRICULUM OF PROF.  Simona Iacobelli

PERSONAL DATA

 

Name and Surname: Simona Iacobelli

Place and date of birth: Rome, IT, 18/10/1971

 

PRESENT POSITION:  Assistant Professor (temp)

 

Department: Biology

Address: via della Ricerca Scientifica

Office: Livello 0, Corridoio G, st. 345, tel 4859

E-mail: simona.iacobelli@uniroma2.it

Office hours: by appointment

 

Academic scientific sector (SSD): MED/01 Medical Statistics

 

                                       

SCIENTIFIC AND TEACHING ACTIVITY

 

Education and academic positions and qualifications:

1996 Master Degree in Statistical and Economical Sciences, Università degli Studi di Roma Sapienza

2002 PhD in Applied Statistics, Università degli Studi di Firenze

2007-2009 Assistant Professor (3-yrs contract), SSD MED/01, Faculty of Medicine, Università del Molise

2009-2015 Assistant Professor (3+3-yrs contract), SSD MED/01, Faculty of Medicine, Università di Roma Tor Vergata

2014 National Scientific Qualification (ASN) as Associate Professor for sector 06/M1 profile MED/01 – Medical Statistics

 

Post-lauream education and professional experiences:

2002-2003 Post-Doc, Dept. Medical Statistics and Bioinformatics, Leiden University Medical Center, Leiden (NL)

2004-2007 Senior Researcher, Gruppo Italiano Malattie Ematologiche dell’Adulto, Roma

2004-oggi Senior Statistician, European group Blood and Marrow Transplantation & Dept. Medical Statistics and Bioinformatics, Leiden University Medical Center, Leiden (NL)

2011-2013 Expert in Biostatistics at the Etical Committee of Istituti Fisioterapici Ospitalieri (IFO) of Rome (National Cancer Institute Regina Elena, Dermatologic Institute San Gallicano)

 

Research activities: best 10 publications  

 

  1. Styczynski J, Tridello G, Gil L, Ljungman P, Hoek J, Iacobelli S, Ward KN, Cordonnier C, Einsele H, Socie G, Milpied N, Veelken H, Chevallier P, Yakoub-Agha I, Maertens J, Blaise D, Cornelissen J, Michallet M, Daguindau E, Petersen E, Passweg J, Greinix H, Duarte RF, Kröger N, Dreger P, Mohty M, Nagler A, Cesaro S. Impact of Donor Epstein-Barr Virus Serostatus on the Incidence of Graft-Versus-Host Disease in Patients With Acute Leukemia After Hematopoietic Stem-Cell Transplantation: A Study From the Acute Leukemia and Infectious Diseases Working Parties of the European Society for Blood and Marrow Transplantation. Journal of Clinical Oncology. 2016 Apr 18
  2. Fioredda F, Iacobelli S, van Biezen JC, Gaspar B, Ancliff P, Donadieu J, Aljurf M, Peters C, Calvillo M, Matthes-Martin S, Morreale G, van’t Veer-Tazelaar N, de Wreede L, Al Seraihy A, Yesilipek A, Fisher A, Bierings M, Ozturk G, Smith O, Veys P, Ljungman P, Peffault Delatour R, de Toledo Codina JS, Or R, Ganser A, Afanasyev B, Wynn R, Kalwak K, Marsh J, Dufour C. Stem cell transplantation in severe congenital neutropenia. Data from the European Society for Blood and Marrow Transplantation. Blood. 2015 Oct 15;126(16):1885-92
  3. Iacobelli S, de Wreede LC, Schönland S, Björkstrand B, Hegenbart U, Gruber A, Greinix H, Volin L, Narni F, Carella AM, Beksac M, Bosi A, Milone G, Corradini P, Friberg K, van Biezen A, Goldschmidt H, de Witte T, Morris C, Niederwieser D, Garderet L, Kröger N and Gahrton G for the EBMT CMWP, Plasma Cell Disorders Subcommittee. Impact of complete remission before and after allogeneic and autologous transplantation in multiple myeloma: results from the EBMT NMAM2000 prospective trial. Bone Marrow Transplant. 2015 Apr;50(4):505-10
  4. Iacobelli S, Carstensen B. Multiple time scales in multi-state models. Statistics in Medicine. 2013 Dec; 32(30): 5315–5327
  5. Lo-Coco F, Avvisati G, Vignetti M, Thiede C, Orlando SM, Iacobelli S, Ferrara F, Fazi P, Cicconi L, Di Bona E, Specchia G, Sica S, Divona M, Levis A, Fiedler W, Cerqui E, Breccia M, Fioritoni G, Salih HR, Cazzola M, Melillo L, Carella AM, Brandts CH, Morra E, von Lilienfeld-Toal M, Hertenstein B, Wattad M, Lübbert M, Hänel M, Schmitz N, Link H, Kropp MG, Rambaldi A, La Nasa G, Luppi M, Ciceri F, Finizio O, Venditti A, Fabbiano F, Döhner K, Sauer M, Ganser A, Amadori S, Mandelli F, Döhner H, Ehninger G, Schlenk RF, Platzbecker U for the Gruppo Italiano Malattie Ematologiche dell’Adulto, the German–Austrian Acute Myeloid Leukemia Study Group, and Study Alliance Leukemia. Retinoic Acid and Arsenic Trioxide for Acute Promyelocytic Leukemia. New England Journal of Medicine. 2013 Jul ; 369(2): 111-121
  6. Styczynski J, Gil L, Tridello G, Ljungman P, Donnelly JP, van der Velden W, Omar H, Martino R, Halkes C, Faraci M, Theunissen K, Kalwak K, Hubacek P, Sica S, Nozzoli C, Fagioli F, Matthes S, Diaz MA, Migliavacca M, Balduzzi A, Tomaszewska A, de la Camara R, van Biezen A, Hoek J, Iacobelli S, Einsele H, Cesaro S on behalf of the Infectious Diseases Working Party of EBMT. Response to rituximab-based therapy and risk factor analysis in Epstein Barr Virus-related lymphoproliferative disorder after hematopoietic stem cell transplant in children and adults: a study from the Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation. Clinical Infectious Diseases. 2013 Sep; 57(6): 794-802
  7. Gahrton G, Iacobelli S, Björkstrand B, Hegenbart U, Gruber A, Greinix H, Volin L, Narni F, Carella AM, Beksac M, Bosi A, Milone G, Corradini P, Schönland S, Friberg K, van Biezen A, Goldschmidt H, de Witte T, Morris C, Niederwieser D, Garderet L, Kröger N. Autologous/reduced-intensity allogeneic stem cell transplantation versus autologous transplantation in multiple myeloma: long-term results of the EBMT-NMAM2000 study. Blood. 2013 Jun 20;121(25):5055-63
  8. Garderet L, Iacobelli S, Moreau P, Dib M, Lafon I, Niederwieser D, Masszi T, Fontan J, Michallet M, Gratwohl A, Milone G, Doyen C, Pegourie B, Hajek R, Casassus P, Kolb B, Chaleteix C, Hertenstein B, Onida F, Ludwig H, Ketterer N, Koenecke C, van Os M, Mohty M, Cakana A, Gorin NC, de Witte T, Harousseau JL, Morris C, Gahrton G. Superiority of the Triple Combination of Bortezomib-Thalidomide-Dexamethasone Over the Dual Combination of Thalidomide-Dexamethasone in Patients With Multiple Myeloma Progressing or Relapsing After Autologous Transplantation: The MMVAR/IFM 2005-04 Randomized, Phase III Trial From the Chronic Leukemia Working Party of the European Society for Blood and Marrow Transplantation. Journal of Clinical Oncology. 2012 Jul 10;30(20):2475-82
  9. Bjorkstrand B, Iacobelli S, Hegenbart U, Gruber A, Greinix H, Volin L, Narni F, Musto P, Beksac M, Bosi A, Milone G, Corradini P, Goldschmidt H, de Witte T, Morris C, Niederwieser D, Gahrton G. Tandem autologous/reduced-intensity allogeneic stem cell transplantation versus autologous transplantation in myeloma: long-term follow-up. Journal of Clinical Oncology. 2011 Aug 1;29(22):3016-2
  10. Morris C, Iacobelli S, Brand R, Bjorkstrand B, Drake M, Niederwieser D, Gahrton G. Benefit and timing of second transplantations in multiple myeloma: clinical findings and methodological limitations in a European Society for Blood and Marrow Transplantation registry study. Journal of Clinical Oncology. 2004 May 1;22(9):1674-81

 

Last Updated on 03/03/2021

CategoryBlog